



ASSOCIATION ANALYSIS FOR BIG DATA RELATED TO
RHEUMATOID ARTHRITIS BASED ON HAPLOTYPE
BLOCK PARTITIONING AND SINGLE NUCLEOTIDE
POLYMORPHISMS

By

Mohamed Nagy Saad Mohamed Elziftawy

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
DOCTOR OF PHILOSOPHY
in
Biomedical Engineering and Systems

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2017

ASSOCIATION ANALYSIS FOR BIG DATA RELATED TO
RHEUMATOID ARTHRITIS BASED ON HAPLOTYPE
BLOCK PARTITIONING AND SINGLE NUCLEOTIDE
POLYMORPHISMS

By
Mohamed Nagy Saad Mohamed Elziftawy

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
DOCTOR OF PHILOSOPHY
in
Biomedical Engineering and Systems

Under the Supervision of

Prof. Dr. Ayman M. Eldeib

Prof. Dr. Olfat G. Shaker

.....
Professor
Biomedical Engineering and Systems
Department
Faculty of Engineering, Cairo University

.....
Professor
Medical Biochemistry and Molecular
Biology Department
Faculty of Medicine, Cairo University

Assoc. Prof. Dr. Mai S. Mabrouk

.....
Associate Professor
Biomedical Engineering Department
Faculty of Engineering, Misr University
for Science and Technology

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2017

ASSOCIATION ANALYSIS FOR BIG DATA RELATED TO
RHEUMATOID ARTHRITIS BASED ON HAPLOTYPE
BLOCK PARTITIONING AND SINGLE NUCLEOTIDE
POLYMORPHISMS

By
Mohamed Nagy Saad Mohamed Elziftawy

A Thesis Submitted to the
Faculty of Engineering at Cairo University
in Partial Fulfillment of the
Requirements for the Degree of
DOCTOR OF PHILOSOPHY
in
Biomedical Engineering and Systems

Approved by the
Examining Committee

Prof. Dr. Mohamed W. T. Fakhr, External Examiner
Computer Engineering Department, AAST

Prof. Dr. Ahmed H. Kandil, Internal Examiner

Prof. Dr. Ayman M. Eldeib, Thesis Main Advisor

Prof. Dr. Olfat G. Shaker, Member
Medical Biochemistry and Molecular Biology Department, Faculty of
Medicine, Cairo University

Assoc. Prof. Dr. Mai S. Mabrouk, Member
Biomedical Engineering Department, MUST

FACULTY OF ENGINEERING, CAIRO UNIVERSITY
GIZA, EGYPT
2017

Engineer's Name: Mohamed Nagy Saad Mohamed
Date of Birth: 20/03/1983
Nationality: Egyptian
E-mail: nagybioeng@yahoo.com
Phone: 01111606852
Address: 11 Ali Elshakh st., Shoubra, Cairo
Registration Date: 01/03/2012
Awarding Date:/..../ 2017
Degree: Doctor of Philosophy
Department: Biomedical Engineering and Systems



Supervisors:

Prof. Ayman M. Eldeib
Prof. Olfat G. Shaker
Medical Biochemistry and Molecular Biology
Department, Faculty of Medicine, Cairo University
Assoc. Prof. Mai S. Mabrouk
Biomedical Engineering Department, MUST

Examiners:

Prof. Mohamed W. T. Fakhr (External examiner)
Computer Engineering Department, AAST
Prof. Ahmed H. Kandil (Internal examiner)
Prof. Ayman M. Eldeib (Thesis main advisor)
Prof. Olfat G. Shaker (Member)
Assoc. Prof. Mai S. Mabrouk (Member)

Title of Thesis:

Association Analysis for Big Data Related to Rheumatoid Arthritis Based on
Haplotype Block Partitioning and Single Nucleotide Polymorphisms

Key Words:

Genetic Association Study; Haplotype Block; Linkage Disequilibrium; Rheumatoid Arthritis; Single Nucleotide Polymorphism

Summary:

Genetics of autoimmune diseases represent a growing domain with surpassing biomarker results with rapid progress. Rheumatoid arthritis (RA) is an autoimmune disease which has a significant socio-economic impact. The exact cause of RA is unknown, but it is thought to have both a genetic and an environmental bases. This thesis is concerned with the methods of identifying the genetic biomarkers of RA. Most of the researchers in the field of identifying RA biomarkers use single nucleotide polymorphism (SNP) approaches to express the significance of their results. Although, haplotype block methods are expected to play a complementary role in the future of that field. The used datasets belong to Egyptian population and North American population. Selection of the method used for the association discovery has a large impact on the resulted biomarkers. Finally, individual SNP approach and haplotype block methods should be applied side by side to discover valuable RA biomarkers.

Acknowledgments

First, thanks **ALLAH**, the most merciful and most gracious, who supplied me with power and faith to work on this very difficult topic.

I would like to express my appreciation and respect towards my advisor, **Prof. Dr. Ayman Mohamed Eldeib**, for his guidance has shaped this work and has presented me valuable skills, which I will take along with me throughout my academic journey. I would like also to thank him for his understanding, patience and enthusiasm.

This gratitude extends to the member of the advisory committee, **Prof. Dr. Olfat Gamil Shaker**, who I am honored to be one of her students. She has not been only providing me an experienced guidance; but she has also been giving me support and confidence to go on. Also, she generously was the provider of the Egyptian population dataset.

I am indeed indebted to my dear friendly advisor **Assoc. Prof. Dr. Mai Said Mabrouk**, who has put the corner stone of this work. She had helped me through scientific fruitful discussions, encouragement, and endless support. Also, she played major role in making the North American Rheumatoid Arthritis Consortium (NARAC) dataset available.

I would like to acknowledge the Genetic Analysis Workshop (GAW) grant (R01 GM031575) for providing the NARAC dataset. This work is based on data that was gathered with the support of grants from the National Institutes of Health (NO1-AR-2-2263, RO1-AR-44422), and the National Arthritis Foundation. NARAC dataset couldn't be available without the support of **Prof. Dr. Jean MacCluer**; Senior Scientist Emeritus at Texas Biomedical Research Institute, and **Mrs. Vanessa Olmo**; Independent Meeting & Event Planning Professional at Business Endeavors, San Antonio, Texas Area.

I also owe great thanks to **Prof. Dr. Hamdy Elrefai Agwa**; Professor, Botany Department, Faculty of Science, Kafr Elsheikh University, for his invaluable help on the introduction of the immune system.

Special thanks go to **Eng. Waleed El-Badry**; Assistant Lecturer in Mechatronics Engineering Department at MUST, for his support in software technical issues.

My deepest gratitude goes to my parents, **Nagy** and **Thanaa**. Every single achievement in my life belongs to them and whenever they should feel proud of me, they should rather be proud of themselves.

This work could not come to light without the patience, extreme help, and encouragement of my precious wife **Doha**. With her assist, I have overcome all the obstacles that I faced in my life. No words can describe her. Really, she is a gift from **ALLAH** to me.

I would also like to thank my sister **Zeinab** for being my lifelong best friend.

Dedication

This thesis is dedicated to the soul of the queen of my heart (my daughter) **Raghad**, may **ALLAH** bless her soul. Every word in this thesis was written with true love, pure love, deep love, renewable love, and endless love to **Raghad**. Every challenging work and achievement was applied to make her expected future happier, easier, and brighter.

Table of Contents

ACKNOWLEDGMENTS	V
DEDICATION.....	VI
TABLE OF CONTENTS.....	VII
NOMENCLATURE.....	XII
ABSTRACT	XVI
CHAPTER 1 INTRODUCTION	1
1.1. OVERVIEW	1
1.2. PROBLEM DEFINITION	1
1.3. OBJECTIVES OF THE THESIS	2
1.4. ORGANIZATION OF THE THESIS.....	3
CHAPTER 2 BACKGROUND & LITERATURE REVIEW.....	5
2.1. INTRODUCTION	5
2.2. IMMUNE SYSTEM.....	5
2.3. RHEUMATOID ARTHRITIS	6
2.4. SINGLE NUCLEOTIDE POLYMORPHISM	7
2.4.1. Types of SNPs.....	8
2.4.2. SNP density.....	9
2.4.3. Haplotype frequency	9
2.4.4. Minor allele frequency	9
2.4.5. Hardy Weinberg equilibrium	10
2.5. LINKAGE DISEQUILIBRIUM	10
2.6. GENETIC ASSOCIATION STUDY	12
2.7. BIG DATA	12
2.8. HAPLOTYPE BLOCK PROJECTS	13
2.8.1. The HapMap project	14
2.8.2. The 1000 genomes project	14
2.8.3. Haplotype block partitioning	14
2.9. RA BIOMARKERS	14
2.9.1. Biomarkers in the MHC region and Chr 6	15
2.9.2. Biomarkers outside MHC region	18
2.9.3. RA biomarkers in children.....	20
2.9.4. Gender specific biomarkers	21
2.9.5. Biomarkers in different populations.....	22
2.10. HAPLOTYPE BLOCKS VS INDIVIDUAL SNPs.....	23
2.11. HAPLOTYPE BLOCKS IN RA BIOMARKER DISCOVERY	24
2.12. STUDIES THAT AGREE/DISAGREE WITH OTHERS	26
2.13. SUMMARY.....	29
CHAPTER 3 METHODS AND MATERIALS.....	31

3.1.	INTRODUCTION	31
3.2.	METHODS.....	31
3.2.1.	Individual SNP approaches.....	31
3.2.1.1.	Odds ratio.....	32
3.2.1.2.	Pearson chi square test.....	32
3.2.2.	Haplotype block methods.....	33
3.2.2.1.	Four gamete test.....	33
3.2.2.2.	Confidence interval test	35
3.2.2.3.	Solid spine of linkage disequilibrium.....	36
.....	36
3.3.	SYSTEM OVERVIEW	37
3.3.1.	Egyptian dataset	37
3.3.2.	NARAC dataset.....	39
3.4.	MATERIALS.....	40
3.5.	SUMMARY	41
CHAPTER 4 RESULTS		45
4.1.	INTRODUCTION	45
4.2.	EGYPTIAN DATASET RESULTS	45
4.2.1.	RA susceptibility results	45
4.2.2.	RA severity results.....	49
4.3.	NARAC DATASET RESULTS	52
4.4.	SUMMARY	55
CHAPTER 5 DISCUSSIONS.....		61
5.1.	INTRODUCTION	61
5.2.	EGYPTIAN DATASET DISCUSSIONS.....	61
5.2.1.	RA susceptibility discussions.....	61
5.2.2.	RA severity discussions	65
5.3.	NARAC DATASET DISCUSSIONS	66
5.4.	SUMMARY	68
CHAPTER 6 CONCLUSION AND FUTURE WORK		71
6.1.	CONCLUSION.....	71
6.1.1.	Egyptian dataset conclusions	71
6.1.1.1.	RA susceptibility.....	71
6.1.1.2.	RA severity	71
6.1.2.	NARAC dataset conclusions.....	72
6.2.	FUTURE WORK	72
REFERENCES		73
APPENDIX: ADDITIONAL NARAC DATASET RESULTS		85

List of Tables

Table 2.1: Haplotype frequencies for a pair of SNPs	11
Table 2.2: Allele frequencies relative to haplotype frequencies	11
Table 2.3: The relationship between the haplotype frequencies, allele frequencies, and (D).....	11
Table 2.4: Detected SNPs associated with RA susceptibility	27
Table 2.5: Studies that agree/disagree with other studies.....	29
Table 3.1: The exposed group and the unexposed group in the individual SNP approaches	32
Table 3.2: The 2*2 contingency table for observed and expected values	33
Table 3.3: Example on recombination events with four haplotypes and four SNPs.....	35
Table 3.4: Example on SSLD	36
Table 3.5: A comparison among haplotype block definitions.....	36
Table 4.1: The biomarker checks of the studied SNPs.....	46
Table 4.2: Case-control RA susceptibility study - SNP analysis	47
Table 4.3: Case-control RA severity study – SNP analysis	50
Table 4.4: The processing time for each performed step	56
Table 4.5: Results of the individual SNP approach.....	57
Table 5.1: Association status for RA susceptibility of our study and previous studies .	62
Table 5.2: Association status for RA severity of our study and previous studies	65
Table 5.3: The ability of each haplotype block method in representing the significant SNPs of the individual SNP approach.....	68
Table A.1: Comparison among haplotype block methods results for Chr one	85
Table A.2: Comparison among haplotype block methods results for Chr two	85
Table A.3: Comparison among haplotype block methods results for Chr three	86
Table A.4: Comparison among haplotype block methods results for Chr four.....	86
Table A.5: Comparison among haplotype block methods results for Chr five	87
Table A.6: Comparison among haplotype block methods results for Chr six.....	87
Table A.7: Comparison among haplotype block methods results for Chr seven	88
Table A.8: Comparison among haplotype block methods results for Chr eight	88
Table A.9: Comparison among haplotype block methods results for Chr nine	89
Table A.10: Comparison among haplotype block methods results for Chr ten	89
Table A.11: Comparison among haplotype block methods results for Chr eleven.....	90
Table A.12: Comparison among haplotype block methods results for Chr twelve.....	90
Table A.13: Comparison among haplotype block methods results for Chr thirteen	91
Table A.14: Comparison among haplotype block methods results for Chr fourteen	91
Table A.15: Comparison among haplotype block methods results for Chr fifteen.....	92
Table A.16: Comparison among haplotype block methods results for Chr sixteen.....	92
Table A.17: Comparison among haplotype block methods results for Chr seventeen ..	93
Table A.18: Comparison among haplotype block methods results for Chr eighteen.....	93
Table A.19: Comparison among haplotype block methods results for Chr nineteen.....	94
Table A.20: Comparison among haplotype block methods results for Chr twenty	94
Table A.21: Comparison among haplotype block methods results for Chr twenty one.	95
Table A.22: Comparison among haplotype block methods results for Chr twenty two	95
Table A.23: Number of significant SNPs discovered by the three haplotype block methods compared to that of the four methods	96
Table A.24: SNP IDs that were uniquely identified by each method	97
Table A.25: Block similarity among the used haplotype block methods for the 22 Chrs	101

List of Figures

Figure 2.1: Four different types of antigens showing the binding between the epitope and the antibody [12].....	6
Figure 2.2: Hand with inflammations due to RA [13].....	7
Figure 2.3: Three persons' DNA with highlighted SNP in the fourth position [18].....	8
Figure 2.4: Types of SNPs.....	9
Figure 2.5: One SNP per 30 bp detected in 2 double strand DNA sequences [25].....	9
Figure 2.6: Summary of the genetic association study [41].....	12
Figure 2.7: A representation of the size and complexity of big data [43].....	13
Figure 2.8: More than 35 risk loci that have been previously identified as biomarkers for RA disease [50].....	15
Figure 2.9: Classification of RA biomarkers depending on different categories.....	15
Figure 2.10: Demonstration of the MHC region [51].....	16
Figure 2.11: LD structure for 12 SNPs at HLA-DRB1 and HLA-DPB1. A constructed block was shown including eight SNPs, from SNP 5 to SNP 12 [52].....	17
Figure 2.12: Case-control association results at 6q23. The associated SNP (rs10499194) was about 165 kb from both TNFAIP3 and OLIG3 genes [79].....	18
Figure 2.13: Manhattan plots of the GWAS meta-analysis for RA in the Japanese population [92].....	21
Figure 2.14: Manhattan plot of association with RA in the European descents [99].....	23
Figure 2.15: Summarization of the "Background and Literature Review" chapter.....	30
Figure 3.1: Block diagram of the used methods.....	31
Figure 3.2: Crossover results in recombination event [141].....	34
Figure 3.3: The FGT is conducted between pairwise loci, and (0) and (1) denote the absence and presence, respectively, of all four gametes between locus pairs [125].....	34
Figure 3.4: The CIT showing the definition of strong LD and weak LD.....	35
Figure 3.5: Morphological structure of SSLD at the legs of the LD chart.....	36
Figure 3.6: System overview for the whole study.....	38
Figure 3.7: A snapshot from the Egyptian dataset showing 10 controls with their corresponding 8 SNPs.....	39
Figure 3.8: A snapshot from the NARAC dataset showing 10 samples with their corresponding 3 SNPs.....	40
Figure 3.9: Flow chart of the proposed study for the Egyptian dataset.....	42
Figure 3.10: Summary of the proposed system for the NARAC dataset.....	43
Figure 4.1: Association analysis for examined SNPs with RA susceptibility. (a) Multiplicative model. (b) Dominant model. (c) Recessive model. (d) Co-dominant model. The horizontal line in each model represents the significance level of the P-value (0.01).....	48
Figure 4.2: Genotype distributions in RA patients and controls.....	48
Figure 4.3: Pairwise LD plot for the VDR SNPs. The rs731236, rs7975232, rs1544410, and rs2228570 correspond to TaqI, ApaI, BsmI, and FokI respectively. (a) D' values. (b) r ² values.....	49
Figure 4.4: Association analysis for examined SNPs with RA severity. (a) Multiplicative model. (b) Dominant model. (c) Recessive model. (d) Co-dominant model. The horizontal line in each model represents the significance level of the P-value (0.05).....	51
Figure 4.5: Genotype distributions in RA patients with and without OP.....	51
Figure 4.6: Pairwise LD plot for examined VDR SNPs. (a) D' values. (b) r ² values.....	52

Figure 4.7: The total no. of blocks resulted from each haplotype block method	53
Figure 4.8: The mean no. of SNPs per each block - either general or significant block for each method	53
Figure 4.9: Median block size in bp for each haplotype block method	54
Figure 4.10: No. of RA biomarkers detected by each method – all or only detected by the method	54
Figure 4.11: Manhattan plot for the associations between genotyped SNPs (Chr 6 of NARAC dataset) and RA susceptibility using individual SNP approach	58
Figure 4.12: Manhattan plot for the associations between the whole NARAC SNPs and RA susceptibility using individual SNP approach	59
Figure 5.1: The overlapping of the significant blocks resulted from the three haplotype block methods.....	69

Nomenclature

A	Adenine
ACPA	Anti Citrullinated Protein Antibody
ACR	American College of Rheumatology
<i>AFF3</i>	AF4/FMR2 Family, Member 3
anti-CCP+	Anti-Cyclic Citrullinated Peptide Positive
<i>ANXA3</i>	Annexin A3
<i>ARAP1</i>	ArfGAP With RhoGAP Domain, Ankyrin Repeat And PH Domain 1
<i>ARID5B</i>	AT Rich Interactive Domain 5B
<i>B3GNT2</i>	UDP-GlcNAc: Beta-1,3-N-Acetylglucosaminyltransferase 2
<i>BLK</i>	B Lymphocyte Kinase
BMD	Bone Mineral Density
Bp	Base Pair
BRASS	Brigham RA Sequential Study
C	Cytosine
<i>C5orf30</i>	Chromosome 5 Open Reading Frame 30
<i>CCL21</i>	Chemokine (C-C Motif) Ligand 21
<i>CCR6</i>	Chemokine (C-C Motif) Receptor 6
CD	Celiac Disease
<i>CD40</i>	Cluster of Differentiation 40
<i>CDK6</i>	Cyclin-Dependent Protein Kinase 6
Chr	Chromosome
CIT	Confidence Interval Test
cM	Centi Morgan
CORA	Childhood Onset of RA
<i>CSF2</i>	Colony Stimulating Factor 2
<i>CTLA4</i>	Cytotoxic T-Lymphocyte Antigen 4
D	Deviation
D'	Normalized Deviation
DAS28	Disease Activity Score in 28 Joints
<i>DC-SIGN</i>	Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin

<i>DDX6</i>	DEAD (Asp-Glu-Ala-Asp) Box Helicase 6
DF	Degree of Freedom
DNA	Deoxyribose Nucleic Acid
DMARDs	Disease-Modifying Anti-Rheumatic Drugs
EIRA	Swedish Epidemiological Investigation of RA
<i>F12</i>	Coagulation Factor 12
<i>FCGR2A</i>	Fc Fragment of IgG, Low Affinity IIa
FGT	Four Gamete Test
FHS	Framingham Heart Study
G	Guanine
GAW	Genetic Analysis Workshop
GCI	Genomics Collaborative Initiative
GENRA	Genetics Network Rheumatology Amsterdam
GPA	Granulomatosis with Polyangiitis
GRAIL	Gene Relationships Across Implicated Loci
<i>GSDMB</i>	Gasdermin B
GWAS	Genome Wide Association Study
<i>HLA</i>	Human Leukocyte Antigen
<i>HSPA1L</i>	Heat Shock 70kDa Protein 1-Like
HWE	Hardy-Weinberg Equilibrium
<i>IFNγ</i>	Interferon Gamma
IGV	Integrative Genomics Viewer
<i>IKZF3</i>	IKAROS Family Zinc Finger 3
<i>IL-1</i>	Interleukin 1 Family
<i>IL2RA</i>	Interleukin 2 Receptor, Alpha
<i>IL6ST</i>	Interleukin 6 Signal Transducer
<i>IRF5</i>	Interferon Regulatory Factor 5
JRA	Juvenile RA
Kb	Kilo Base Pair
<i>KCNB1</i>	Potassium Voltage-Gated Channel, Shab-Related Subfamily, Member 1
<i>KIF5A</i>	Kinesin Family Member 5A
LD	Linkage Disequilibrium
LUMC	Leiden University Medical Center

MAF	Minor Allele Frequency
Mb	Mega Base Pair
<i>MCP-1</i>	Monocyte Chemotactic Protein-1
MHC	Major Histocompatibility Complex
<i>MMEL1</i>	Membrane Metallo-Endopeptidase-Like 1
mRNA	Messenger Ribonucleic Acid
<i>MTHFR</i>	Methylenetetrahydrofolate Reductase
MyEIRA	Malaysian Epidemiological Investigation of RA
NARAC	North American Rheumatoid Arthritis Consortium
<i>NF-kB</i>	Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
<i>NFKBIE</i>	NF-kB Inhibitor, Epsilon
NHS	Nurses Health Study
NICRAP	National Inception Cohort of RA Patients
NK	Natural Killers
<i>NKAPL</i>	NF-kB Activating Protein-Like
ObsHET	Observed Heterozygosity
<i>OLIG3</i>	Oligodendrocyte Transcription Factor 3
OP	Osteoporosis
OR	Odds Ratio
<i>ORMDL3</i>	ORM1-Like 3
<i>PADI4</i>	Peptidyl-Arginine Deiminase Type 4
<i>PDE2A</i>	Phosphodiesterase 2A
<i>PHF19</i>	PHD Finger Protein 19
<i>PIP4K2C</i>	Phosphatidylinositol-5-Phosphate 4-Kinase, Type II, Gamma
<i>PLD4</i>	Phospholipase D Family, Member 4
<i>PRDM1</i>	PR Domain Zinc Finger Protein 1
PredHET	Predicted Heterozygosity
<i>PRKCQ</i>	Protein Kinase C Theta Type
<i>PTPN22</i>	Protein Tyrosine Phosphatase Non-Receptor Type 22
<i>PTPRC</i>	Protein Tyrosine Phosphatase Receptor Type C
<i>PXK</i>	PX Domain Containing Serine/Threonine Kinase
r ²	Correlation Coefficient
RA	Rheumatoid Arthritis
<i>RAG1</i>	Recombination Activating Gene 1

<i>RBPJ</i>	Recombination Signal Binding Protein For Immunoglobulin Kappa J Region
<i>REL</i>	Reticuloendotheliosis
RF	Rheumatoid Factor
SD	Standard Deviation
<i>SE</i>	Shared Epitope
<i>SH2B3</i>	SH2B Adaptor Protein 3
SLE	Systemic Lupus Erythematosus
SNP	Single Nucleotide Polymorphism
SONORA	Study of New Onset RA
<i>SPRED2</i>	Sprouty-Related, EVH1 Domain Containing 2
SSLD	Solid Spine of LD
<i>STAT4</i>	Signal Transducer And Activator of Transcription 4
T	Thymine
<i>TAGAP</i>	T Cell Activation RhoGTPase Activating Protein
<i>TGFβ1</i>	Transforming Growth Factor Beta 1
<i>Th1</i>	T Helper 1 Cells
<i>TNFα</i>	Tumor Necrosis Factor Alpha
<i>TNFB</i>	Tumor Necrosis Factor Beta
<i>TNFAIP3</i>	TNF Alpha-Induced Protein 3
<i>TNFR</i>	TNF Receptor
<i>TNFRSF14</i>	TNFR Superfamily Member 14
<i>TRAF1-C5</i>	TNF Receptor-Associated Factor 1 – Complement Component 5
<i>UBASH3A</i>	Ubiquitin Associated And SH3 Domain Containing A
<i>UBE2L3</i>	Ubiquitin-Conjugating Enzyme E2L3
UKRAG	United Kingdom RA Genetics
USNHGRI	US National Human Genome Research Institute
<i>VDR</i>	Vitamin D Receptor
WRDDB	Wichita Rheumatic Disease Data Bank
WTCCC	Wellcome Trust Case Control Consortium
<i>ZNF</i>	Zinc Finger Protein
χ^2	Pearson Chi Square Test